Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Open a printable version of this pageEmail the URL of this page to a friend
Longest survival follow-up ever reported for immunotherapy treatment in this setting
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
Hepatitis B infects over 40 million people in India
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Subscribe To Our Newsletter & Stay Updated
